Dispensary of Hope, a Nashville-based organization with a national model of medication access for the most vulnerable, has appointed Robert “Bob” Pollock, M.S., Senior Advisor, Outside Director to the Board at Lachman Consultants, Inc. to its National Advisory Council. The organization’s many years of growth and commitment to serve are empowered by individual servants and organizations. This innovative model unifies pharmaceutical manufacturing and safety net healthcare delivery with a common goal of saving and transforming lives.
In announcing the appointment, Christopher Palombo, Dispensary of Hope CEO, stated “I am pleased to welcome Bob Pollock to Dispensary of Hope’s National Advisory Council. Bob was instrumental in shaping the generic drug industry as it began to accelerate–with an emphasis on safety and quality. His many years of dedication are an asset to Dispensary of Hope–providing education, insight, ideas, and encouragement.”
Bob’s esteemed career has earned him deep respect among government and industry. Bob and his wife have a longstanding commitment to the community and are now formally extending that to Dispensary of Hope.
Dispensary of Hope’s National Advisory Council is represented by individuals from medication manufacturing, healthcare delivery, medication distribution, and business and faith communities, from across the nation. It is the Council’s responsibility to provide guidance on the direction of the Dispensary of Hope, to accelerate awareness of the mission, and to advance the collaborative ethos of the Council.
In acknowledging his appointment, Bob commented, “I’ve long admired and appreciated the work of Dispensary of Hope. The opportunities that I’ve had to advise and encourage them are cherished. I am honored to serve on the National Advisory Council. The work that Dispensary of Hope does really moves my heart and that’s why I’ve continued to help them serve. It’s truly making a difference in the lives of people who are suffering and I’m proud to be part of this work.”
Bob’s FDA experience, culminating as the Acting Deputy Director of the Office of Generic Drugs, enables him to provide expert advice and assistance on all aspects of FDA and Regulatory filings. He is well-versed in the intricacies of International Harmonization Issues, regulatory strategies, standards and filing issues, resolution of FDA regulatory matters, as well as in the resolution of patent/exclusivity issues.
We congratulate Bob on this well-deserved recognition.
You can read the Dispensary of Hope announcement here: